Basal and one-month differed neutrophil, lymphocyte and platelet values and their ratios strongly predict the efficacy of checkpoint inhibitors immunotherapy in patients with advanced BRAF wild-type melanoma

Table 2 Clinical outcomes of the entire population to checkpoint inhibitors immunotherapy

ORR overall response rate, SD stable disease lasting 6 months or more, DCR disease control rate (major responses + SD lasting 6 months or more), PD progressive disease (non-responders + SD lasting less than 6 months), PFS progression free survival, OS overall survival

ISSN: 1479-5876